Success Metrics

Clinical Success Rate
58.3%

Based on 7 completed trials

Completion Rate
58%(7/12)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
5(38%)

Phase Distribution

Ph phase_1
5
38%
Ph phase_2
4
31%
Ph not_applicable
3
23%
Ph early_phase_1
1
8%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
4(30.8%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

53.8%

7 of 13 finished

Non-Completion Rate

46.2%

6 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(7)
Terminated(6)

Detailed Status

Completed7
Terminated5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
58.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (7.7%)
Phase 15 (38.5%)
Phase 24 (30.8%)
N/A3 (23.1%)

Trials by Status

completed754%
terminated538%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

NCT01163487
terminatedphase_1

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

NCT00004261
terminatedphase_1

Imaging and Biomarkers of Hypoxia in Solid Tumors

NCT01123005
completedphase_2

EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00041028
completedphase_2

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

NCT02154399
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01163487Phase 1

Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Completed
NCT00004261Phase 1

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

Terminated
NCT01123005Phase 1

Imaging and Biomarkers of Hypoxia in Solid Tumors

Terminated
NCT00041028Phase 2

EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Completed
NCT02154399Phase 2

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

Completed
NCT00049140Phase 2

EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer

Completed
NCT00049231Not Applicable

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

Completed
NCT00107445Phase 2

EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

Completed
NCT00087191Not Applicable

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Terminated
NCT00003282Phase 1

EF5 in Treating Patients With Solid Tumors

Completed
NCT00110032Phase 1

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

Terminated
NCT00896961Not Applicable

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

Terminated
NCT01055678Early Phase 1

To Evaluate the Characteristics of a Breast Cancer

Withdrawn

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13